Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematology
•
Diabetes
•
Endocrinology
•
Primary Care
Do you routinely monitor INR when starting GLP1 R agonist therapy on patients taking warfarin?
Related Questions
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
Which patients would benefit most from teplizumab therapy to delay the onset of T1DM?
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
Do you avoid empagliflozin in patients with history of amputation?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
How do you approach the use of metformin in the management of prediabetes for patients who are neither obese nor have a family history of diabetes?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
When do you recommend screening patients with T2DM for heart failure?
Do you regularly counsel younger women of childbearing age about the impact of Tirzepatide on oral hormonal contraception?
